There are five melanocortin receptors, they are distributed across tissues with nothing obvious in common, and they share a ligand family. That combination is what makes the medicinal chemistry difficult: a compound that engages one tends to engage others, and the receptors it engages incidentally sit in unrelated systems.
| Receptor | Principal distribution described in the literature |
|---|---|
| MC1R | Melanocytes; pigmentation biology |
| MC2R | Adrenal cortex; responds to ACTH rather than the α-MSH family |
| MC3R | Central nervous system; energy homeostasis research |
| MC4R | Central nervous system; the most studied of the group |
| MC5R | Exocrine tissue |
MC2R is the outlier and worth noting early: it responds to ACTH and not to the α-MSH-derived ligands that engage the others, which is why it rarely appears in discussions of this compound group.
Why the ligands overlap
The natural melanocortins — α-MSH, β-MSH, γ-MSH and ACTH — all derive from a single precursor protein, proopiomelanocortin, cleaved differently in different tissues. They share a core sequence motif, and that shared motif is what the receptors recognise. A synthetic analogue built on the same motif therefore has a structural basis for engaging several receptors at once.
Selectivity has to be engineered against that starting point rather than inherited from it, which is the central difficulty of the field and the reason these compounds differ from one another in the specific ways they do.
Where the catalogue compounds sit
- Melanotan-1 — an α-MSH analogue whose literature centres on MC1R and pigmentation biology. How it differs from Melanotan-2 is a question of selectivity rather than strength.
- Melanotan-2 — a cyclic analogue described as non-selective across the family, engaging several receptors rather than one. Its research profile follows from that breadth.
- PT-141 — bremelanotide, a metabolite of Melanotan-2, studied predominantly in relation to central MC4R and MC3R signalling rather than pigmentation.
One more compound derives from this family without acting on it: KPV is the C-terminal tripeptide of α-MSH, retaining an anti-inflammatory literature while lacking the receptor activity that needs the rest of the hormone.
How does a metabolite end up as a separate research compound?
Because breakdown does not always mean inactivation. PT-141 differs from Melanotan-2 by the loss of a terminal group, and that change shifts the receptor engagement profile — away from the pigmentation-associated pathway and toward central receptors. A metabolite with a different selectivity profile is, functionally, a different compound, and it gets studied as one.
Why is cyclisation so common in this family?
Linear peptides are conformationally flexible and open to attack at both termini. Closing the molecule into a ring removes the free termini that exopeptidases act on and fixes a shape that would otherwise flicker between conformations. Since receptor binding depends on presenting the right shape, constraining that shape can raise both stability and selectivity — which is why cyclic analogues recur throughout melanocortin chemistry.
What does this mean for interpreting an in-vitro result?
That the receptor has to be specified, not assumed. An effect observed in a system expressing several melanocortin receptors cannot be attributed to one of them without either a selective antagonist, a knockout, or a single-receptor expression system. Published work in this family is careful about this distinction, and secondary summaries frequently are not.
Does a non-selective compound have research value?
Yes, and framing selectivity as straightforwardly better misses the point. A broadly active compound is a useful tool for asking whether a family is involved at all; a selective one is needed to ask which member. They answer different questions, and a study design should specify which question is being asked before choosing.
Reading the family rather than the compound
The practical value of holding all five receptors in mind is that it explains why these compounds are not interchangeable and why their literatures diverge so sharply despite a shared structural origin. Approached individually they look like three loosely related molecules. Approached as a family, the differences are the point.
What the receptor distribution implies for study design
The scattered tissue distribution is not a curiosity — it determines what a given experimental system can and cannot tell you. A melanocyte model reports on MC1R biology and is silent about the central receptors. A neuronal preparation reports on MC3R and MC4R and says nothing about pigmentation. There is no single system in which the family can be observed whole, which is why the literature is fragmented across sub-fields that rarely cite each other.
The practical consequence is that a compound described as "active at melanocortin receptors" without specifying which, in what system, is carrying almost no information. Reading this family well means reading the methods section first.
Why is MC2R usually excluded from the group?
Because it does not respond to the same ligands. MC2R binds ACTH and not the α-MSH-derived analogues that engage MC1R and MC3R–MC5R, which means a compound built on the α-MSH motif has no meaningful interaction with it. Including MC2R in a selectivity discussion about these compounds is a category error, though it appears in summaries often enough to be worth naming.
How is selectivity actually measured?
By binding affinity or functional potency at each receptor separately, in cells expressing one receptor at a time, and reported as a ratio between them. A compound with a ten-fold preference for one receptor over another is selective in a weak sense; a hundred-fold preference is selective in a useful one. A claim of selectivity without the ratio, and without naming the comparator receptor, is not a measurement — and comparing those ratios across papers requires that both used molar concentrations, which is not always the case.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
